Exploratory data analysis on across all outcomes.
| Outcomes and conditions | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of participants, studies, and interventions in for each condition in each outcome | |||||||||||
| placebo | intervention | interventions | classes | total | |||||||
| participants | studies | interventions | participants | studies | interventions | participants | studies | interventions | |||
| adverse | |||||||||||
| neuropathic | 809 | 7 | 1 | 2221 | 15 | 4 | amitriptyline; duloxetine; venlafaxine; desvenlafaxine | tca; snri | 3030 | 15 | 5 |
| Total | 809 | 7 | 1 | 2,221 | 15 | 4 | — | — | 3,030 | 15 | 5 |
| mood | |||||||||||
| neuropathic | 164 | 3 | 1 | 1013 | 10 | 5 | amitriptyline; duloxetine; citalopram; venlafaxine; duloxetine | tca; snri; ssri | 1177 | 10 | 6 |
| Total | 164 | 3 | 1 | 1,013 | 10 | 5 | — | — | 1,177 | 10 | 6 |
| pain_int | |||||||||||
| neuropathic | 23 | 1 | 1 | 434 | 6 | 5 | amitriptyline; citalopram; nortriptyline; duloxetine; duloxetine | tca; ssri; snri | 457 | 6 | 6 |
| Total | 23 | 1 | 1 | 434 | 6 | 5 | — | — | 457 | 6 | 6 |
| pain_sub | |||||||||||
| neuropathic | 622 | 4 | 1 | 1446 | 7 | 2 | duloxetine; venlafaxine | snri | 2068 | 7 | 3 |
| Total | 622 | 4 | 1 | 1,446 | 7 | 2 | — | — | 2,068 | 7 | 3 |
| physical | |||||||||||
| neuropathic | 366 | 5 | 1 | 768 | 7 | 3 | duloxetine; amitriptyline; duloxetine | snri; tca | 1134 | 7 | 4 |
| Total | 366 | 5 | 1 | 768 | 7 | 3 | — | — | 1,134 | 7 | 4 |
| qol | |||||||||||
| neuropathic | 447 | 4 | 1 | 811 | 5 | 1 | duloxetine | snri | 1258 | 5 | 2 |
| Total | 447 | 4 | 1 | 811 | 5 | 1 | — | — | 1,258 | 5 | 2 |
| withdrawal | |||||||||||
| neuropathic | 1262 | 15 | 1 | 3115 | 26 | 8 | amitriptyline; trazodone; duloxetine; desipramine; fluoxetine; venlafaxine; nortriptyline; desvenlafaxine | tca; sari; snri; ssri | 4377 | 26 | 9 |
| Total | 1,262 | 15 | 1 | 3,115 | 26 | 8 | — | — | 4,377 | 26 | 9 |